Ignite Creation Date:
2025-12-25 @ 2:01 AM
Ignite Modification Date:
2025-12-27 @ 11:57 AM
Study NCT ID:
NCT06749860
Status:
RECRUITING
Last Update Posted:
2024-12-27
First Post:
2024-12-12
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression
Sponsor:
Shanghai Pulmonary Hospital, Shanghai, China
Organization: